Genzyme Corporation

Michael Kothe

John L Kane, Jr

Markus Metz

Andrew Scholte

Jinyu Liu

Tieu-Binh Le

Barret Giese

Claude Barberis

Vinod Francis Patel

John L Kane

Gloria Matthews

Mark Czekaj

Liang Ma

Linli Wei

Paul Erdman

Patrick Wai-Kwok Shum

Patrick Shum

Jr Kane John L

Compounds of the formula or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same. The compounds are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

Colony stimulating factor-1 receptor (CSF-1R) inhibitors

Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Tropomyosin-related kinase (trk) inhibitors

Tropomyosin-related kinase (Trk) inhibitors

Tropomyosin-related kinase (TRK) inhibitors

Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

Growing community of inventors

Medway, MA, United States of America

Michael Kothe